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Abstract
Purpose Radiolabelled peptides used for peptide receptor
radionuclide therapy are excreted mainly via the kidneys
and are partly reabsorbed and retained in the proximal
tubular cells. The resulting high renal radiation dose can
cause nephrotoxicity, limiting the maximum activity dose
and the effectiveness of peptide receptor radionuclide
therapy. The mechanisms of kidney reabsorption of these
peptides are incompletely understood, but the scavenger
receptor megalin has been shown to play a role in the
reabsorption of 111In-octreotide. In this study, the role of
megalin in the renal reabsorption of various relevant
radiolabelled peptides was investigated.
Methods Groups of kidney-specific megalin-deficient mice
and wild-type mice were injected with 111In-labelled
somatostatin, exendin, neurotensin or minigastrin ana-
logues. Single photon emission computed tomographic
(SPECT) images of the kidneys were acquired and analysed
quantitatively, or the animals were killed 3 h after injection
and the activity concentration in the kidneys was measured.
Results Megalin-deficient mice showed significantly lower
uptake of all studied radiolabelled peptides in the kidneys,
ranging from 22% (111In-octreotide) to 65% (111In-exendin)
of uptake in wild-type kidneys. Quantitative analysis of
renal uptake by SPECT and ex vivo measurements showed
a very good correlation.
Conclusion Megalin is involved in the renal reabsorption of
radiolabelled octreotide, octreotate, exendin, neurotensin
and minigastrin. This knowledge may help in the design of
strategies to reduce this reabsorption and the resulting
nephrotoxicity in peptide receptor radionuclide therapy,
enabling more effective therapy. Small-animal SPECT is an
accurate tool, allowing in vivo quantification of renal
uptake and serial measurements in individual mice.
Keywords Kidney .Megalin . Peptide receptor radionuclide
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Introduction
In peptide receptor radionuclide therapy (PRRT), radio-
labelled peptide analogues are used to target tumours
expressing particular receptors, such as the somatostatin
receptor. Most radiolabelled peptides are predominantly
cleared from the body via the kidneys. Rapid clearance of
the radiolabelled peptides from the blood and low retention in
the kidneys minimize the radiation dose to normal tissues.
However, part of the filtered load of these small proteins and
peptides is reabsorbed from the ultrafiltrate in the proximal
tubules. Evidence suggests that, after glomerular filtration,
Erik Vegt and Marleen Melis contributed equally to this work.
E. Vegt :A. Eek :M. Brom :W. J. G. Oyen :M. Gotthardt :
O. C. Boerman
Department of Nuclear Medicine,
Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands
M. Melis :M. de Visser :M. de Jong
Department of Nuclear Medicine, Erasmus MC,
Rotterdam, The Netherlands
E. Vegt (*)
Department of Nuclear Medicine, GROW School for Oncology &
Developmental Biology, Maastricht University Medical Centre,
PO Box 5800, 6202 AZ Maastricht, The Netherlands
e-mail: ErikVegt@gmail.com
Eur J Nucl Med Mol Imaging (2011) 38:623–632
DOI 10.1007/s00259-010-1685-9
proteins and peptides in the ultrafiltrate bind to endocytic
receptors at the luminal surface of proximal tubular cells and are
internalized. Subsequently, the compounds are transferred to the
lysosomes, where they are proteolytically degraded into amino
acids [1]. These are transported back into the bloodstream.
However, residualizing radiolabels (e.g. N-terminal amino acid
chelate conjugates or lysine chelate conjugates) are trapped in
the tubular cell lysosomes and can deliver high radiation doses
to the kidney tubules and glomeruli [2]. Nephrotoxicity is
dose-limiting in PRRT with somatostatin analogues such as
90Y-DOTA-Tyr3-octreotide [3, 4].
The receptors involved in the tubular reabsorption of
peptides have not yet been completely characterized, but for
various nonradiolabelled peptides the involvement of mega-
lin has been shown [5]. Megalin is a multiligand receptor
belonging to the LDL receptor family. The receptor contains
four large cysteine-rich ligand-binding domains and is a
high-capacity pathway for the reabsorption of different
structurally nonrelated peptides and proteins such as albu-
min, vitamin D binding protein, β2-microglobulin and
aprotinin [5, 6]. De Jong et al. recently reported that the
renal uptake of 111In-octreotide is significantly lower in
kidney-specific megalin-deficient mice than in their wild-
type counterparts, implicating the involvement of megalin in
the renal reabsorption of radiolabelled somatostatin ana-
logues [7]. Many other radiolabelled peptides that are being
studied for their potential in tumour imaging and PRRT
display renal retention severalfold higher than octreotide.
Examples include exendin and minigastrin, targeting
glucagon-like peptide-1 and cholecystokinin2 receptors,
respectively [8, 9]. It is unknown whether megalin is also
involved in the renal uptake of these peptides.
In clinical PRRT with somatostatin analogues, the
standard renoprotective regimen nowadays consists of
coinfusion of basic amino acids, which are thought to
interfere with the binding of somatostatin analogues to
megalin or other endocytic receptors on the proximal tubular
cells [10, 11]. However, Gotthardt et al. have shown that the
renal uptake of 111In-minigastrin is not reduced significantly
by coinfusion of basic amino acids [9], suggesting that the
reabsorption of this peptide is mediated by other receptors.
Knowledge about the molecular mechanisms of proximal
tubular reabsorption of different radiolabelled peptides is
important to devise new methods to reduce their renal
retention, for example by selecting or designing more
efficient inhibitors of their renal reabsorption, or by
structurally modifying the peptides to reduce their binding
to renal receptors.
In this study, the role of megalin in the renal retention
of [111In-DTPA-D-Phe1]-octreotide (111In-octreotide),
[111In-DTPA0-D-Phe1,Tyr3]-octreotate (111In-octreotate),
[Lys40(111In-DTPA)]-exendin-3 (111In-exendin), [111In-
DOTA-Glu1]-minigastrin (111In-minigastrin) and [111In-
DTPA0]-neurotensin (111In-neurotensin) [6–13] was
studied in mice. The renal uptake of the peptides was
measured by single photon emission computed tomogra-
phy (SPECT) imaging and by ex vivo measurements of
kidney-specific megalin-deficient mice (megalinlox/lox;
apoECre [12]) and wild-type mice. Since the level of renal
uptake of radiopeptides may differ between female and
male mice [13], both genders were imaged by SPECT.
Materials and methods
Animals
The megalin-deficient mice used were megalinlox/lox;
apoECre mice [12]. The principles of creating tissue-
specific gene knockout models are described in detail
elsewhere [14, 15]. In brief, in megalinlox/lox; apoECre mice,
expression of the enzyme Cre recombinase is controlled by
the apolipoprotein E (apoE) promoter, and is thus produced
only in tissues where the apoE gene is transcribed. In these
tissues, Cre recombinase excises sequences from the
genome that are flanked by two loxP sequences, in this
case the megalin gene [14]. Animals were bred locally
using males heterozygous for the apoECre gene. Offspring
expressing the apoECre gene were identified by means of
polymerase chain reaction (PCR) analysis as described
below. Animals not expressing the apoECre gene (mega-
linlox/lox mice) were used as the wild type in the
biodistribution studies. In the SPECT studies, C57Bl/6
mice were used as the wild type.
PCR analysis
For PCR the primers CCCAAGAAGAGGAAGGTG
(forward) and GCTGGCCCAAATGTTGCTG (reverse)
were used. The reaction mixture consisted of approxi-
mately 50 ng mouse DNA in a total of 25 μl colourless
PCR buffer (Go Taq Flexi reaction buffer, Promega) with
5 mM MgCl2 (Promega), 0.5 mM deoxyribonucleotide
triphosphate mix (dNTP, Promega), 12.5 pmol forward
primer, 12.5 pmol reverse primer and 2.5 IU Taq
polymerase (Promega). This mixture was heated for
4 min at 95°C, followed by 32 cycles of 30 s at 95°C,
30 s at 56°C and 30 s at 72°C. After cycling, the
temperature was maintained at 72°C for 10 min and
subsequently lowered to 10°C. The DNA formed was
analysed by agarose gel electrophoresis.
Radiolabelled compounds
The following peptide derivatives were studied: [DTPA-D-
Phe1]-octreotide (Covidien) [16], [DTPA0-D-Phe1,Tyr3]-
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octreotate (Biosynthema) [17], [DTPA0]-neurotensin [6–13]
(Biosynthema) [18], [Lys40-DTPA]-exendin-3 (exendin,
Peptide Specialty Laboratories) [19], and [DOTA-Glu1]-
minigastrin (Peptide Specialty Laboratories) [20]. Relevant
properties of the peptides are summarized in Table 1.
Peptides were labelled with 111InCl3 (20 MBq/nmol for
SPECT studies, 10–80 MBq/nmol for ex vivo biodistribu-
tion studies) as described previously [21]. Labelling
efficiency and radiochemical purity of the labelled
peptides were determined by silica gel instant thin-layer
chromatography and reverse-phase high-performance
liquid chromatography. Radiochemical purity was >95%
for all compounds.
SPECT studies
Megalin-deficient and wild-type mice (male and female,
four to six per group) received an intravenous injection of
40 MBq (0.2 ml, 2 nmol) 111In-octreotide. The exact
injected activity was determined by measuring the syringe
in a dose calibrator before and after injection. A 24-min
SPECT scan of the kidney region was acquired 3 and 24 h
after injection with a four-headed helical NanoSPECT/CT
system (Bioscan) using Nucline software (v 2.01, Mediso).
Multipinhole mouse collimators with nine pinholes (1.4 mm
diameter) per head were used, with a matrix of 256 × 256
and 24 projections (2 min per projection). During the scan
the animals were anaesthetized with isoflurane/O2 and body
temperature was maintained. This procedure was repeated in
the same mice with 111In-octreotate, 111In-exendin, 111In-
neurotensin and 111In-minigastrin consecutively at intervals
of at least 3 weeks. Some of the animals developed signs of
kidney damage at the end of this series of experiments,
probably caused by the relatively high renal uptake of 111In-
exendin, resulting in a high radiation dose to the kidneys
[22]. Therefore, the 111In-exendin, 111In-neurotensin and
111In-minigastrin data were discarded and an extra experi-
ment with these peptides was carried out in a new set of
animals. To reduce the risk of kidney damage, the injected
activity of 111In-minigastrin and 111In-exendin was reduced
to 10 MBq, while the peptide dose was kept constant at
2 nmol. In this second series, SPECT scans were acquired
only 3 h after injection.
SPECT scans were reconstructed iteratively using
InVivoScope software (v 1.32, Bioscan) with medium
noise reduction, a voxel size of 0.3 mm3 and standard
reconstruction settings. The amount of radioactivity in a
volume of interest drawn around the kidneys was quanti-
fied and expressed as percent of injected dose per gram
tissue (%ID/g). To achieve accurate quantification, the
camera was calibrated by scanning a 20-ml polypropylene
tube mouse phantom filled with a known amount of 111In
activity.
After the final SPECT scan, the animals were killed and
the biodistribution of 111In-minigastrin and 111In-exendin
was determined as described in the next section to confirm
the accuracy of the SPECT measurements.
Ex vivo biodistribution studies
Animals (four to six per group) received an intravenous
injection of 0.4 MBq (0.2 ml, 5–40 pmol) 111In-octreotide,
111In-exendin, 111In-neurotensin or 111In-minigastrin. For
111In-octreotide the experiment was performed with male
and female mice; for the other peptides only female mice
were used. The animals were killed 3 h after injection, and
organs were dissected. The biodistribution of the 111In-
labelled peptides was determined by weighing the organs
and measuring the radioactivity in a gamma counter.
Measured activity was expressed as %ID/g. The right
kidney of each animal was cut in half. One half was snap-
frozen in liquid nitrogen and processed for cryosectioning,
the other half was processed for paraffin sectioning. Frozen
10-μm sections were mounted on glass slides for autoradi-
ography. A phosphor imaging screen was exposed to the
sections for 2 days and scanned using a BAS 1800-II
phosphor imager (Fujifilm).
Immunohistochemistry
Frozen 5-μm kidney sections were fixed in 4% formalin for
10 min. After rinsing with 0.05% polysorbate 80 in PBS,
the sections were incubated with goat anti-rat megalin
polyclonal antibody (SC-16478, Santa Cruz) 10 μg/ml in
PBS with 5% BSA for 1 h at room temperature, followed
by incubation with horseradish peroxidase-conjugated
donkey anti-goat IgG, F(ab')2 (SC-3851, Santa Cruz) 1/
100 for 30 min at room temperature. Peroxidase activity
was visualized with diaminobenzidine (Powervision) and
nuclei were counterstained using haematoxylin. Slides were
dehydrated with ethanol and xylene and embedded in slide
mounting fluid (Permount), after which they were studied
microscopically. Megalin expression was scored visually by
an independent, blinded observer on an arbitrary scale of 0
(negative) to 4 (all tubules positive).
Statistical analysis
Data are presented as mean values±standard deviation.
Renal uptake values were compared using Student’s t-test.
For the SPECT studies of 111In-minigastrin and 111In-
exendin (after which the mice were killed), the correlation
between renal uptake measured on the SPECT images and
uptake in the same mice measured ex vivo was determined.
Spearman’s rank correlation coefficient was calculated with
SPSS 16.0 (SPSS).
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Results
Immunohistochemistry
Immunostaining revealed lower expression of megalin in
the kidney cortex of the megalin-deficient mice as
compared to the wild-type mice. The expression of megalin
in the megalin-deficient kidneys varied considerably,
ranging from almost absent (score 0) to moderate expres-
sion (score 2). Examples are shown in Fig. 1.
SPECT measurement of renal peptide uptake
As shown in Fig. 2, the kidneys were visualized very well
on the SPECT scans acquired at 3 h after injection. The
images indicated that the radioactivity mainly accumulated
in the renal cortex.
The measured renal uptake values of the 111In-labelled
peptides as derived from the SPECT images at 3 h after
injection and the ratios of uptake between megalin-deficient
mice and wild-type mice are presented in Table 2. The data
are summarized together with the ex vivo biodistribution
data in Fig. 3. 111In-exendin expressed the highest renal
uptake: 371±35 %ID/g in female wild-type mice. The
peptide with the lowest renal uptake (15±2.7 %ID/g in
female wild-type mice) was 111In-neurotensin. In the
SPECT studies, the renal retention of all 111In-labelled
peptides was significantly lower in megalin-deficient mice
than in wild-type mice, both in males and females. The
effect was most prominent for 111In-neurotensin, for which
the renal uptake in female megalin-deficient mice was only
23% of the uptake in wild-type mice (p < 0.0001). The least
effect was observed with 111In-exendin, for which the
uptake in female megalin-deficient mice was 62% of the
uptake in wild-type mice (p = 0.003).
The data measured 24 h after injection are presented in
Table 2. The renal uptake of the studied radiolabelled
peptides remained significantly lower in the megalin-
deficient mice, both in females and in males. Overall, the
uptake of 111In-octreotide and 111In-octreotate was signifi-
cantly lower in male mice than in female mice: the retention
of 111In-octreotide in males was too low to delineate the
kidneys and the uptake of 111In-octreotate was more than
threefold lower in males than in females. For 111In-exendin,
no difference between the genders was observed.
Ex vivo measurement of renal uptake
The renal uptake of the 111In-labelled peptides measured ex
vivo in megalin-deficient and wild-type mice is presented in
Table 3 and summarized in Fig. 3. The renal uptake of 111In-
octreotide, 111In-octreotate, 111In-minigastrin and 111In-neu-
rotensin was significantly lower in the megalin-deficient
mice than in the wild-type mice. The effect was most
prominent for 111In-octreotide, for which the renal uptake in
female megalin-deficient mice was only 22% of the uptake
in wild-type mice (p = 0.0007). For 111In-exendin, no
significant difference in renal uptake between the two groups
was observed when a peptide dose of 5 pmol was used.
However, when a higher peptide dose of 2 nmol was
Table 1 Characteristics of studied peptide analogues
Peptide analogue Target receptor Molecular weight (kDa) Number of amino acid residues (positive/negative) Charge at pH 7
111In-Octreotide Somatostatin receptor2 1.5 8 (1+/0−) +1
111In-Octreotate Somatostatin receptor2 1.5 8 (1+/0−) +1
111In-Exendin Glucagon-like peptide-1 4.8 39 (4+/6−) −2
111In-Minigastrin Cholecystokinin2 and gastrin 2.1 13 (0+/7−) −7
111In-Neurotensin Neurotensin 1.3 8 (1+/0−) +1
Fig. 1 Anti-megalin immunostaining of kidney cortex from a wild-type mouse (a) and from two megalin-deficient mice exhibiting relatively high
(b) and relatively low (c) residual expression of megalin
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administered for SPECT imaging, a significant difference
was measured, both on SPECT and ex vivo (see Table 3).
Autoradiography of the kidneys revealed a patchy
distribution of the 111In-labelled peptides, mainly in the renal
cortex (Fig. 4), and confirmed lower uptake in the kidneys of
the megalin-deficient mice.
Biodistribution of 111In-labelled octreotide, octreotate,
neurotensin and minigastrin in organs other than the kidneys
did not differ significantly between the wild-type and
megalin-deficient mice (data not shown). For the high dose
of 111In-exendin (2 nmol), lung uptake in the wild-type
animals was significantly higher than in the megalin-
Fig. 2 SPECT images of the
kidneys of wild-type (a) and
megalin-deficient (b) mice 3 h
after injection of 111In-minigas-
trin (left maximum intensity
projections, right coronal slices)
Table 2 Renal uptake of radiolabelled peptides on SPECT in wild-type and megalin-deficient mice
Peptide Gender Wild-type (%ID/g±SD) Megalin-deficient (%ID/g±SD) Ratio megalin-deficient/wild-type
3 h after injection
111In-Octreotide Female 17±2.4 8.5±2.6 49% (p = 0.001)
Male 22±5.6 5.7±2.0 26% (p = 0.0003)
111In-Octreotate Female 16±4.6 7.6±2.4 46% (p = 0.007)
Male 16±2.8 5.9±1.9 36% (p = 0.0001)
111In-Exendin Female 371±35 230±58 62% (p = 0.003)
Male 328±51 171±34 52% (p = 0.001)
111In-Minigastrin Female 89±10 33±8.9 37% (p < 0.0001)
Male 104±13 52±14 49% (p = 0.0003)
111In-Neurotensin Female 15±2.7 3.6±1.18 23% (p < 0.0001)
Male 18±9.0 4.6±1.1 25% (p = 0.02)
24 h after injection
111In-Octreotide Female 2.2±0.25 1.4±0.47 64% (p = 0.0001)
Male Not measurable Not measurable –
111In-Octreotate Female 5.3±0.97 2.5±0.71 47% (p = 0.001)
Male 1.6±0.37 0.44±0.20 28% (p = 0.0003)
111In-Exendin Female 148±11 82±24 55% (p = 0.0005)
Male 142±10 69±19 49% (p = 0.0001)
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Fig. 3 Renal uptake of 111In-
labelled peptides in wild-type
and megalin-deficient mice, as
measured by ex vivo biodistri-
bution studies and SPECT 3 h
after injection. Results are
presented as mean %ID/g; error
bars indicate standard error of
the mean. *p < 0.05
628 Eur J Nucl Med Mol Imaging (2011) 38:623–632
deficient mice (1.2±0.18 %ID/g vs. 0.23±0.037 %ID/g in
females, and 0.98±0.039 %ID/g vs. 0.26±0.034 %ID/g in
males; both p<0.0001). However, in the animals that
received the low dose of 5 pmol 111In-exendin, no difference
in lung uptake was observed: in both the wild-type and the
megalin-deficient mice, lung uptake was 11 %ID/g, much
higher than in the animals that received 2 nmol of peptide.
Correlation between biodistribution and SPECT
The correlation between renal uptake values measured by
biodistribution and SPECT was very good, as depicted in
Fig. 5. Spearman’s rank correlation coefficient was 0.924
(r2=0.85, p < 0.0005).
Discussion
In the present study we showed that the multiligand
receptor megalin is involved in the proximal tubular
reabsorption of 111In-octreotate, 111In-minigastrin, 111In-
neurotensin and probably of 111In-exendin, and we
confirmed megalin’s role in the reabsorption of 111In-
octreotide: the renal uptake of these peptides in megalin-
deficient mice was reduced to 23–65% of the uptake in
wild-type mice. The remaining renal uptake of the radio-
labelled peptides in the megalin-deficient mice may have
been due to residual megalin expression. The knock-out of
megalin expression in the kidneys of these megalinlox/lox;
apoECre mice occurs in a mosaic pattern, with a consi-
derable percentage of tubular cells expressing normal
levels of megalin, presumably caused by insufficient
Table 3 Renal uptake of radiolabelled peptides measured ex vivo 3 h after injection in wild-type and megalin-deficient mice
Peptide Gender Wild-type (%ID/g±SD) Megalin-deficient (%ID/g±SD) Ratio megalin-deficient/wild-type
111In-Octreotide Female 38±9.8 8.4±3.5 22% (p = 0.0007)
Male 25±12 7.9±2.7 32% (p = 0.03)
111In-Exendin 2 nmola Female 331±33 215±34 65% (p = 0.001)
111In-Exendin 5 pmola Female 225±35 183±39 81% (ns)
111In-Minigastrin Female 66±5.9 17±9.1 26% (p < 0.0001)
111In-Neurotensin Female 5.1±0.94 1.7±0.18 34% (p < 0.0001)
ns not significant.
a 111 In-Exendin was measured ex vivo in two experiments: after the final SPECT scan using 2 nmol peptide, and in a separate biodistribution experiment
using 5 pmol peptide.
Fig. 5 Correlation between renal uptake measured ex vivo and uptake
measured by SPECT. The data are from individual mice that were studied
ex vivo after the final SPECT scan (111In-minigastrin and 111In-exendin).
Solid lines linear-fitted trend line with 95% confidence interval
Fig. 4 Autoradiography of kidneys of wild-type and megalin-
deficient mice that received 111In-exendin (a), 111In-minigastrin (b)
or 111In-neurotensin (c)
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expression of Cre recombinase. Leheste et al. initially
reported that approximately 10% of the proximal tubular
cells of these mice express normal levels of megalin [12],
and Motoyoshi et al. reported residual megalin expression
in 35–50% of proximal tubular cells [23]. Immunohisto-
chemical staining of kidney sections in the present study
confirmed residual megalin expression and considerable
variation between individual mice. In addition to residual
expression of megalin, part of the residual uptake may
also be explained by the involvement of other uptake
mechanisms in the reabsorption of these peptides, such as
fluid phase endocytosis [24] or other receptors. Proximal
tubular expression of ligand-specific receptors for somato-
statin, glucagon-like peptide-1 and cholecystokinin2 has
been described [25–27]. Cubilin, another multiligand
receptor, is dependent on other transmembrane proteins
such as megalin and amnionless for its internalization [28,
29]. In megalin-deficient mice, the internalization of
cubilin may therefore also be reduced.
The data obtained in the current study with 111In-exendin
were paradoxical: significantly reduced renal uptake in
megalin-deficient mice was measured when the animals
received an imaging dose of 2 nmol, but no significant
difference between the two groups was found at a
biodistribution dose of 5 pmol 111In-exendin. This paradox
may very well be caused by the residual megalin expression
in the megalin-deficient mice. The residual megalin
receptors may still be able to internalize much of the 5
pmol dose, while they are saturated by the 2 nmol dose.
Even though proximal tubular endocytosis is regarded as a
low-specificity, high-capacity pathway, it can be blocked
competitively by excesses of ligands [30, 31]. The
difference between 111In-exendin and the other peptides in
this respect might be explained by a relatively high affinity
of 111In-exendin for megalin and/or associated receptors
such as cubilin. This may also account for the very high
baseline renal uptake of this peptide (225–371 %ID/g) and
suggests that megalin is indeed involved in the renal
reabsorption of 111In-exendin.
The renal uptake of the radiolabelled peptides at
3 h after injection was similar in male and female
mice. However, at 24 h after injection the uptake of
111In-octreotide and 111In-octreotate was significantly
lower in male mice, which has been reported previously
[13]. This suggests that the proximal tubular processing
and retention of 111In-labelled somatostatin analogues
differ between male and female mice, leading to more
rapid washout of radioactivity in males. However, the
ratios of uptake between megalin-deficient and wild-
type mice were comparable in both genders at both time-
points, which suggests that the role of megalin in the
reabsorption of radiopeptides is independent of gender
influences.
Reduced proximal tubular reabsorption of radiolabelled
peptides would be expected to cause increased excretion of
the radiolabelled peptides in the urine without affecting
plasma clearance, since glomerular filtration is not affected
and reabsorbed radiolabelled peptides are not returned to
the bloodstream. This was confirmed by our observation
that the radioactivity concentrations of these radiolabelled
peptides in the blood and in most organs other than the
kidneys did not differ between megalin-deficient and wild-
type mice. The one exception, lower uptake of 111In-
exendin in the lungs of megalin-deficient mice, was only
observed at the high peptide dose of 2 nmol. At the lower
dose of 5 pmol, no difference between megalin-deficient
and wild-type animals was observed, and lung uptake was
approximately 5-fold to 20-fold higher than in the 2-nmol
groups. The lower uptake at the higher peptide dose was
most likely due to saturation of specific lung uptake, which
has also been described recently by Brom et al. [19]. The
lower lung uptake in the megalin-deficient mice in this
group may indicate involvement of megalin in the
pulmonary uptake of this peptide. Megalin is expressed in
the lungs [32], and this high-capacity receptor may
contribute significantly to peptide uptake at higher concen-
trations, when specific glucagon-like peptide-1 receptor
mediated uptake (high affinity but lower capacity) is
saturated. Although the megalinlox/lox; apoECre mice are
described as kidney-specific megalin-deficient mice [12],
apoE is also expressed in the lungs [33], which may cause
reduced expression of megalin in the lungs of these
animals. Possible lower expression of megalin in the lungs
is unlikely to have affected the renal uptake of the studied
peptides, as their concentrations in blood and other organs
did not differ significantly between the megalin-deficient
and wild-type mice.
In this study the renal uptake measured ex vivo and
on SPECT images correlated very well, which confirms
the previously reported accuracy of the small-animal
SPECT system [34]. SPECT enables serial measurements
in vivo and possibly the reuse of animals in multiple
experiments. However, SPECT remains much less sensi-
tive than ex vivo organ measurement, which means that
only organs with a considerable uptake can reliably be
imaged and relatively high radiation doses have to be
administered. This can lead to complications: in the
present study, mice that received a relatively high kidney
radiation dose from 111In-exendin developed long-term
kidney damage, which has been described and analysed in
detail elsewhere [22]. In addition, high activity doses
require administration of a relatively high peptide dose,
which can influence a peptide’s pharmacokinetics and
biodistribution [19, 35].
Our results indicate that megalin plays an important
role in the renal reabsorption of these diverse 111In-
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labelled peptides. The variety of radiolabelled peptides
and other ligands that are taken up via megalin suggests
that it may also be involved in the renal reabsorption of
other radiolabelled peptides. The knowledge that megalin
is involved in the renal uptake of these radiolabelled
peptides may help in the development of new strategies
for the reduction of PRRT-induced nephrotoxicity. For
example, the reduction in renal uptake of radiolabelled
peptides by coadministration of compounds such as
succinylated gelatin and albumin fragments [21, 36–38],
is probably due to their competitive binding to megalin.
Lysine, a positively charged amino acid, is used to reduce
nephrotoxicity of clinical somatostatin analogue PRRT
[10]. However, Gotthardt et al. have shown that lysine
does not reduce the renal uptake of negatively charged
minigastrin analogues, whereas negatively charged poly-
glutamic acids do reduce uptake of 111In-minigastrin, but
not of the positively charged 111In-octreotide [9]. These
observations suggest that different mechanisms are
involved in the uptake of these radiolabelled peptides
and seems to contradict our present findings that megalin
is involved in the renal uptake of both peptides.
However, megalin contains four large binding domains
[6], and lysine and polyglutamic acid may bind selec-
tively to distinct regions of these domains, thereby only
interfering with the binding of specific radiolabelled
peptides. The peptide mixtures in succinylated gelatin
and albumin fragments are more likely to block several
of megalin’s binding regions, thereby interfering with the
binding and uptake of several different radiolabelled
peptides.
In conclusion, the multiligand receptor megalin plays an
important role in the renal reabsorption of 111In-labelled
octreotide, octreotate, minigastrin, exendin and neurotensin.
This knowledge may be used in the development of new
methods to reduce the renal retention of these peptides, thus
reducing the risk of nephrotoxicity and improving the
safety and effectiveness of PRRT.
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